Netupitant + Palonosetron

Thông tin thuốc gốc
Chỉ định và Liều dùng
Prophylaxis of chemotherapy-induced nausea and vomiting
Adult: Available preparation:
Netupitant 300 mg and palonosetron 0.5 mg
1 cap approx 1 hour prior to initiation of each chemotherapy cycle.
Renal Impairment
Severe or ESRD: Contraindicated.
Hepatic Impairment
Severe (Child-Pugh score >9): Contraindicated.
Chống chỉ định
Severe hepatic and renal (including ESRD) impairment. Pregnancy and lactation.
Thận trọng
Patient with history of constipation or signs of subacute intestinal obstruction; history of QT prolongation, CHF, bradyarrhythmia, electrolyte abnormalities, and conduction disturbance.
Phản ứng phụ
Significant: Hypersensitivity (including anaphylaxis), constipation with faecal impaction.
Blood and lymphatic system disorders: Neutropenia, leucocytosis.
Cardiac disorders: Cardiomyopathy, bundle branch block, atrio-ventricular block, conduction disorder.
Gastrointestinal disorders: Dyspepsia, abdominal distension, abdominal pain, flatulence, nausea, hiccups, diarrhoea.
General disorders and administration site conditions: Fatigue, asthenia.
Investigations: Increased hepatic transaminases, blood alkaline phosphatase, creatine phosphokinase, and creatinine; prolonged QT interval, abnormal ST-T segment.
Metabolism and nutrition disorders: Decreased appetite.
Musculoskeletal and connective tissue disorders: Weakness.
Nervous system disorders: Headache, dizziness, vertigo.
Psychiatric disorders: Somnolence, insomnia.
Skin and subcutaneous tissue disorders: Erythema, alopecia, urticaria.
Vascular disorders: Hypertension.
Potentially Fatal: Serotonin syndrome.
Thông tin tư vấn bệnh nhân
This drug may cause fatigue, dizziness, and somnolence, if affected, do not drive or operate machinery.
Monitor for signs of serotonin syndrome (e.g. mental status and neuromuscular changes, autonomic instability, gastrointestinal symptoms). Obtain liver and renal function. Perform pregnancy test on all pre-menopausal women prior to treatment.
Tương tác
Increased risk of serotonin syndrome with SSRIs and SNRIs.
Netupitant: Plasma concentration is increased by CYP3A4 inhibitors (e.g. ketoconazole) and decreased by CYP3A4 inducers (e.g. rifampicin). Increases exposure to dexamethasone, etoposide, docetaxel, midazolam, erythromycin.
Tác dụng
Description: Netupitant is a selective human substance P/neurokinin (NK1) receptor antagonist which increases the antiemetic activity of 5-HT3 receptor antagonists and corticosteroids, thereby inhibiting acute and delayed emesis associated with chemotherapy.
Palonosetron is a selective 5-HT3 receptor antagonist which blocks serotonin on peripheral vagal nerve terminals in the periphery and centrally in the chemoreceptor trigger zone.
Absorption: Netupitant: Time to peak plasma concentration: Approx 5 hours.
Palonosetron: Well absorbed. Absolute bioavailability: Approx 97%.
Distribution: Netupitant: Volume of distribution: 1,982 ± 906 L. Plasma protein binding: >99.5% (netupitant); >97% (major metabolites).
Palonosetron: Volume of distribution: 8.3 ± 2.5 L/kg. Plasma protein binding: Approx 62%.
Metabolism: Netupitant: Extensively metabolised in the liver mainly by CYP3A4, and to a lesser extent by CYP2C9 and CYP2D6, to form active metabolites M1, M2, and M3.
Palonosetron: Metabolised by CYP2D6, CYP3A4, and CYP1A2 to form inactive metabolites N-oxide-palonosetron and 6-S-hydroxy-palonosetron.
Excretion: Netupitant: Mainly via faeces (approx 71%); urine (approx 4%). Elimination half-life: 80 ± 29 hours.
Palonosetron: Mainly via urine (85-93%, 40% as unchanged drug); faeces (5-8%). Elimination half-life: 48 ± 19 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Netupitant, CID=6451149, (accessed on Jan. 22, 2020)

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Palonosetron, CID=6337614, (accessed on Jan. 22, 2020)

Bảo quản
Store between 20-25°C.
Phân loại MIMS
Phân loại ATC
A04AA55 - palonosetron, combinations ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.
Akynzeo Capsule (Eisai Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 30/01/2018.

Anon. Netupitant and Palonosetron. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 30/01/2018.

Buckingham R (ed). Netupitant. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 30/01/2018.

Buckingham R (ed). Palonosetron Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 30/01/2018.

Joint Formulary Committee. Palonosetron with Netupitant. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 30/01/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Netupitant + Palonosetron từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in